X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4379) 4379
Publication (351) 351
Book Review (77) 77
Book Chapter (52) 52
Magazine Article (18) 18
Dissertation (15) 15
Conference Proceeding (11) 11
Data Set (3) 3
Government Document (2) 2
Journal / eJournal (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
memantine (3065) 3065
humans (1916) 1916
index medicus (1609) 1609
male (1383) 1383
animals (1318) 1318
memantine - therapeutic use (1133) 1133
alzheimer's disease (1068) 1068
neurosciences (1052) 1052
pharmacology & pharmacy (917) 917
female (884) 884
memantine - pharmacology (882) 882
dementia (829) 829
alzheimer disease - drug therapy (780) 780
rats (750) 750
aged (665) 665
receptors, n-methyl-d-aspartate - antagonists & inhibitors (661) 661
psychiatry (624) 624
clinical neurology (593) 593
alzheimers-disease (559) 559
donepezil (545) 545
glutamate (530) 530
excitatory amino acid antagonists - therapeutic use (513) 513
excitatory amino acid antagonists - pharmacology (496) 496
cholinesterase inhibitors - therapeutic use (468) 468
double-blind (465) 465
treatment outcome (394) 394
mice (390) 390
middle aged (385) 385
methyl aspartate (354) 354
dose-response relationship, drug (343) 343
drug therapy (338) 338
aged, 80 and over (319) 319
memantine - administration & dosage (317) 317
brain (307) 307
analysis (303) 303
rivastigmine (298) 298
adult (287) 287
receptors, n-methyl-d-aspartate - metabolism (281) 281
cholinesterase inhibitors (278) 278
moderate (278) 278
geriatrics & gerontology (273) 273
efficacy (271) 271
neurology (271) 271
nmda receptor (271) 271
rats, sprague-dawley (270) 270
memantine - adverse effects (249) 249
neurons (238) 238
disease models, animal (237) 237
double-blind method (236) 236
galantamine (228) 228
nervous system agents (225) 225
amantadine (222) 222
neuroprotection (221) 221
alzheimers disease (220) 220
memory (215) 215
article (210) 210
dementia - drug therapy (210) 210
dopamine agents - therapeutic use (209) 209
rats, wistar (209) 209
placebo-controlled trial (205) 205
nootropic agents - therapeutic use (204) 204
drug therapy, combination (203) 203
care and treatment (198) 198
clinical trials (198) 198
neurons - drug effects (197) 197
time factors (197) 197
cholinesterase-inhibitors (192) 192
piperidines - therapeutic use (192) 192
research (191) 191
indans - therapeutic use (189) 189
cognition (180) 180
drugs (177) 177
neuropsychological tests (177) 177
nmda (174) 174
alzheimer’s disease (171) 171
neuroprotective agents - pharmacology (169) 169
nmda receptor antagonist (169) 169
neurodegenerative diseases (165) 165
brain - drug effects (161) 161
severity of illness index (158) 158
glutamic acid receptors (156) 156
biochemistry & molecular biology (153) 153
cognitive ability (153) 153
long-term potentiation (153) 153
excitotoxicity (152) 152
dizocilpine maleate - pharmacology (151) 151
excitatory amino acid antagonists - administration & dosage (150) 150
medicine, general & internal (149) 149
activities of daily living (148) 148
n-methyl-d-aspartic acid receptors (147) 147
cells, cultured (146) 146
controlled-trial (145) 145
hippocampus (145) 145
mk-801 (144) 144
rat (144) 144
alzheimer disease - psychology (141) 141
alzheimer disease (140) 140
neuroprotective agents - therapeutic use (140) 140
nmda receptors (140) 140
cognition disorders - drug therapy (137) 137
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4020) 4020
German (145) 145
Spanish (75) 75
Russian (67) 67
French (36) 36
Japanese (28) 28
Chinese (17) 17
Polish (12) 12
Portuguese (10) 10
Dutch (9) 9
Korean (8) 8
Persian (7) 7
Czech (6) 6
Turkish (6) 6
Italian (5) 5
Danish (4) 4
Norwegian (2) 2
Serbian (2) 2
Finnish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Romanian (1) 1
Slovak (1) 1
Slovenian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 10, pp. 893 - 903
Journal Article
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 02/2018, Volume 28, Issue 4, pp. 689 - 693
Journal Article
ACS Chemical Neuroscience, ISSN 1948-7193, 09/2017, Volume 8, Issue 9, pp. 1823 - 1829
Journal Article
Journal Article
CNS Drugs, ISSN 1172-7047, 06/2013, Volume 27, Issue 6, pp. 469 - 478
Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer's disease (AD). This study evaluated the efficacy,... 
DEMENTIA | PSYCHIATRY | PERFORMANCE | BEHAVIORAL SYMPTOMS | COGNITIVE IMPAIRMENT | PSYCHOLOGICAL SYMPTOMS | CLINICAL NEUROLOGY | NEUROPSYCHIATRIC INVENTORY | SPANISH VERSION | DONEPEZIL | COST | CLINICAL-TRIALS | PHARMACOLOGY & PHARMACY | Excitatory Amino Acid Antagonists - therapeutic use | Excitatory Amino Acid Antagonists - pharmacokinetics | United States | Humans | Male | Alzheimer Disease - diagnosis | Dose-Response Relationship, Drug | Female | Drug Therapy, Combination | Excitatory Amino Acid Antagonists - adverse effects | Memantine - administration & dosage | Alzheimer Disease - psychology | Severity of Illness Index | Memantine - pharmacokinetics | Argentina | Double-Blind Method | Drug Administration Schedule | Alzheimer Disease - drug therapy | Excitatory Amino Acid Antagonists - administration & dosage | Treatment Outcome | Alzheimer Disease - enzymology | Cholinesterase Inhibitors - administration & dosage | Cholinesterase Inhibitors - adverse effects | Mexico | Aged | Cholinesterase Inhibitors - therapeutic use | Memantine - therapeutic use | Delayed-Action Preparations | Memantine - adverse effects | Dosage and administration | Research | Drug therapy | Alzheimer's disease | Cholinesterase inhibitors | Studies | Blister packs | Nuclear magnetic resonance--NMR | Laboratories | Older people | Compensation | Clinical trials | Clinical medicine | Pharmaceutical industry | Drug dosages | Patients
Journal Article
Journal Article